Research Peptides.
Elevated Standards.

GLP-RT3: Triple Receptor Research Overview

GLP-RT3 is the Revel catalog identifier for a material described as retatrutide, an investigational peptide studied for activation of three distinct hormone receptors: GLP-1, GIP and glucagon. The informal term “GLP-3” refers to this three-receptor mechanism; it is not the name of a separate GLP hormone or an official drug class. Material identity must be verified against lot-specific analytical records.

1. GLP-1 receptor — satiety and glucose signaling

GLP-1 receptor activation influences appetite and satiety pathways in the brain, enhances glucose-dependent insulin secretion, reduces inappropriate glucagon secretion in high-glucose conditions and slows gastric emptying. Together, these mechanisms can affect food intake and post-meal glucose regulation.

2. GIP receptor — nutrient-response signaling

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone. Activating its receptor can amplify insulin release when blood glucose is elevated. GIP-related signaling also interacts with adipose tissue and energy-balance pathways; the contribution of GIP activation to the overall effects of a triple agonist remains an active research topic.

3. Glucagon receptor — hepatic and energy-use pathways

Glucagon receptor activation engages liver pathways involved in mobilizing energy and regulating hepatic glucose production. Researchers are also evaluating how this pathway influences energy expenditure and substrate use. Glucagon signaling can raise blood glucose, so the combined metabolic response must be understood in the context of all three receptors rather than assuming each has the same effect.

Why study the three receptors together?

The research hypothesis is that coordinated signaling through GLP-1, GIP and glucagon receptors may influence appetite, glucose homeostasis and energy expenditure in complementary ways. Clinical investigations of retatrutide have reported changes in body weight and glycemic measures, but trial results are not evidence that a separately supplied research material is equivalent to the investigational clinical product.

Research status and documentation

Retatrutide remains investigational and is not FDA-approved for general medical use. This listing is for research information only; it is not a treatment recommendation or a claim of safety or efficacy for a supplied lot. Before any product release, confirm chemical identity, strength, purity, relevant testing, chain of custody and applicable buyer eligibility. Packaging images are representative. Not for human or veterinary administration.

Scientific references: Jastreboff et al., New England Journal of Medicine (2023), doi:10.1056/NEJMoa2301972; Eli Lilly, “What to know about retatrutide.”

GLP-RT3: Triple Receptor Research Overview

GLP-RT3 is the Revel catalog identifier for a material described as retatrutide, an investigational peptide studied for activation of three distinct hormone receptors: GLP-1, GIP and glucagon. The informal term “GLP-3” refers to this three-receptor mechanism; it is not the name of a separate GLP hormone or an official drug class. Material identity must be verified against lot-specific analytical records.

1. GLP-1 receptor — satiety and glucose signaling

GLP-1 receptor activation influences appetite and satiety pathways in the brain, enhances glucose-dependent insulin secretion, reduces inappropriate glucagon secretion in high-glucose conditions and slows gastric emptying. Together, these mechanisms can affect food intake and post-meal glucose regulation.

2. GIP receptor — nutrient-response signaling

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone. Activating its receptor can amplify insulin release when blood glucose is elevated. GIP-related signaling also interacts with adipose tissue and energy-balance pathways; the contribution of GIP activation to the overall effects of a triple agonist remains an active research topic.

3. Glucagon receptor — hepatic and energy-use pathways

Glucagon receptor activation engages liver pathways involved in mobilizing energy and regulating hepatic glucose production. Researchers are also evaluating how this pathway influences energy expenditure and substrate use. Glucagon signaling can raise blood glucose, so the combined metabolic response must be understood in the context of all three receptors rather than assuming each has the same effect.

Why study the three receptors together?

The research hypothesis is that coordinated signaling through GLP-1, GIP and glucagon receptors may influence appetite, glucose homeostasis and energy expenditure in complementary ways. Clinical investigations of retatrutide have reported changes in body weight and glycemic measures, but trial results are not evidence that a separately supplied research material is equivalent to the investigational clinical product.

Research status and documentation

Retatrutide remains investigational and is not FDA-approved for general medical use. This listing is for research information only; it is not a treatment recommendation or a claim of safety or efficacy for a supplied lot. Before any product release, confirm chemical identity, strength, purity, relevant testing, chain of custody and applicable buyer eligibility. Packaging images are representative. Not for human or veterinary administration.

Scientific references: Jastreboff et al., New England Journal of Medicine (2023), doi:10.1056/NEJMoa2301972; Eli Lilly, “What to know about retatrutide.”

GLP-TR2 (tirzepatide): Mechanism and Research Overview

Dual activation of GIP and GLP-1 receptors.

GIP receptor

GIP is an incretin pathway supporting glucose-dependent insulin secretion and nutrient-responsive signaling.

GLP-1 receptor

GLP-1 receptor activation influences satiety, gastric emptying and glucose-dependent insulin secretion.

Research significance

Dual incretin signaling is studied for effects on metabolic physiology. Clinical evidence from approved tirzepatide medicines does not validate a separately sourced research material.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: Frias et al., NEJM (2021), doi:10.1056/NEJMoa2107519.

NAD+: Mechanism and Research Overview

Nicotinamide adenine dinucleotide is a cellular coenzyme, not a peptide.

NAD+/NADH

NAD+ accepts electrons and becomes NADH in metabolic redox reactions; mitochondrial pathways recycle these cofactors.

Sirtuins and PARPs

These enzyme families use NAD+ as a substrate in protein regulation and DNA damage responses.

Research significance

Researchers study NAD+ metabolism in energy homeostasis, stress response and aging biology. Mechanistic studies do not establish the effectiveness of a particular formulation.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: Covarrubias et al., Nature Reviews Molecular Cell Biology (2021), doi:10.1038/s41580-020-00313-x.

BPC-157: Mechanism and Research Overview

An experimental peptide studied largely in preclinical models. No single definitive human receptor target has been established.

Tissue-response hypotheses

Animal and cellular investigations have examined endothelial signaling, tissue repair markers and angiogenesis-related pathways; human clinical validation is lacking.

Inflammatory signaling

Experimental studies examine nitric oxide-related mechanisms, inflammatory mediators and responses to induced injury, but findings remain preliminary.

Research significance

Research into BPC-157 is exploratory. Animal outcomes cannot support claims that a supplied product treats injuries or accelerates healing in humans.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: FDA safety discussion concerning BPC-157; peer-reviewed preclinical literature.

BPC-157 / TB500 blend: Mechanism and Research Overview

Two-component investigational mixture whose component identities must be verified individually. TB500 is an inconsistently used label and may refer to a thymosin beta-4 fragment rather than full-length thymosin beta-4.

BPC-157 hypotheses

Laboratory studies examine endothelial, inflammatory and tissue-response mechanisms, without established therapeutic receptors in humans.

Thymosin beta-4-related biology

Full-length thymosin beta-4 binds actin and participates in cytoskeletal dynamics; a fragment sold as TB500 cannot automatically be assumed biologically equivalent.

Research significance

No well-controlled clinical evidence establishes the benefits or safety of combining these components. Both molecular identities and mixture stability require analytical confirmation.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: Thymosin beta-4 cell migration research; FDA BPC-157 safety discussion.

PT-141 (bremelanotide): Mechanism and Research Overview

A melanocortin receptor agonist investigated for central nervous system sexual-response signaling.

Melanocortin receptors

Bremelanotide activates melanocortin receptors; MC4R is implicated in brain circuits affecting motivation and sexual response.

Other physiological effects

Melanocortin networks also affect energy-balance pathways. Clinical bremelanotide may cause nausea and transient blood pressure increases.

Research significance

An FDA-approved prescription bremelanotide formulation exists for a narrow indication; a separately sourced research product is not that approved medicine.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: FDA Vyleesi prescribing information.

HCG (human chorionic gonadotropin): Mechanism and Research Overview

A glycoprotein hormone involved in reproductive endocrinology; its biological potency is expressed in international units rather than milligrams.

LH/CG receptor

hCG activates the LH/choriogonadotropin receptor (LHCGR), stimulating cAMP-related steroidogenesis pathways in responsive tissues.

Reproductive signaling

LHCGR is involved in ovarian function, corpus luteum activity, and testicular Leydig cell signaling.

Research significance

Research includes endocrine mechanisms, reproductive physiology and assay development. An RUO material is not interchangeable with approved prescription hCG products.

Research status and documentation

This listing does not establish safety or efficacy for human or animal use. Product identity, stated strength, analytical results, and lot documentation must be confirmed before any release. Representative product imagery only; not for human or veterinary administration.

Reference context: Endotext: human chorionic gonadotropin physiology; FDA hCG labeling.

KLOW 80 mg research material. Exact active components, proportions and molecular identities require confirmation before descriptive claims can be made.

Representative packaging only. Lot records and quality documentation require independent verification. Not for human or veterinary administration. Not available to purchase.